Skip to main content

Jazz Pharma Plc(JAZZ-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low198.00
Day High204.01
Open:203.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
StockStory
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
JAZZ
Tipranks
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), KalVista Pharmaceuticals (KALV) and TScan Therapeutics (TCRX)
Tipranks
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Wells Fargo
Tipranks
RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Tipranks
Piper Sandler Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Tipranks
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
StockStory
1 Value Stock to Research Further and 2 We Ignore
PUBM
StockStory
3 Healthcare Stocks Walking a Fine Line
BDX
Tipranks
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Jazz Pharmaceuticals (JAZZ) and Talkspace (TALK)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ)
Tipranks
Jazz Pharmaceuticals Balances Record Gains With Slower 2026
Motley Fool
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
Tipranks
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays
Tipranks
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ) and Baxter International (BAX)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: InfuSystem Holdings (INFU), Jazz Pharmaceuticals (JAZZ)
Tipranks
Stifel Nicolaus Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Tipranks
Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Tipranks
RBC Capital Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Tipranks
Morgan Stanley Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Tipranks
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Tempus AI, Inc. Class A (TEM)
StockStory
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
JAZZ
StockStory
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales
JAZZ
StockStory
Jazz Pharmaceuticals Earnings: What To Look For From JAZZ
JAZZ
StockStory
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
ELV
StockStory
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid
ZS
StockStory
3 Cash-Producing Stocks We Think Twice About
JACK
Tipranks
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)
Motley Fool
$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24%
Motley Fool
This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding
Motley Fool
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

Profile

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.